The present Invention relates an Antibody or an Antigen binding fragment, comprising of heavy chain CDR sequences selected from the group consisting of: SEC ID: 1,3,5, US13,15,21,23,25,33,35 and 37, also includes light chain CDR sequences selected from the group consisting of: 7,9,11,17,19,27,29,31,39,41,43 and 65.It also refers that the Antibody is able to bind specifically to Human pd-1, blocking the binding to its ligand induced production of il-2 in CD4 + T cells, among others.Also refers to a polynucleotide, a Vector comprising the polynucleotide, a cell that includes the Vector and a host cell.A Pharmaceutical composition comprising the Antibody or Antigen binding Fragment. It is useful for the treatment of multiple cancers through the Modulation of the immune function of Human.La presente invencion refiere un anticuerpo o un fragmento de union a antigeno del mismo, que comprende secuencias de CDR de cadena pesada seleccionadas del grupo que consiste en: SEC ID NOs: 1,3,5,13,15,21,23,25,33,35 y 37, comprende tambien secuencias de CDR de cadena ligera seleccionadas del grupo que consiste en: 7,9,11,17,19,27,29,31,39,41,43 y 65. Tambien refiere que el anticuerpo es capaz de unirse especificamente a PD-1 humana, bloqueando la union a su ligando induciendo la produccion de IL-2 en celulas T CD4+,entre otros modos. Tambien refiere a un polinucleotido, un vector que comprende el polinucleotido, una celula que comprende el vector y una celula huesped. Refiere una composicion farmaceutica que comprende al anticuerpo o fragmento de union a antigeno. Es util para el tratamiento de canceres multiples mediante la modulacion de la funcion inmune humana.
